Your browser doesn't support javascript.
loading
No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome?
Fayet, Yohan; Chevreau, Christine; Decanter, Gauthier; Dalban, Cécile; Meeus, Pierre; Carrère, Sébastien; Haddag-Miliani, Leila; Le Loarer, François; Causeret, Sylvain; Orbach, Daniel; Kind, Michelle; Le Nail, Louis-Romée; Ferron, Gwenaël; Labrosse, Hélène; Chaigneau, Loïc; Bertucci, François; Ruzic, Jean-Christophe; Le Brun Ly, Valérie; Farsi, Fadila; Bompas, Emmanuelle; Noal, Sabine; Vozy, Aurore; Ducoulombier, Agnes; Bonnet, Clément; Chabaud, Sylvie; Ducimetière, Françoise; Tlemsani, Camille; Ropars, Mickaël; Collard, Olivier; Michelin, Paul; Gantzer, Justine; Dubray-Longeras, Pascale; Rios, Maria; Soibinet, Pauline; Le Cesne, Axel; Duffaud, Florence; Karanian, Marie; Gouin, François; Tétreau, Raphaël; Honoré, Charles; Coindre, Jean-Michel; Ray-Coquard, Isabelle; Bonvalot, Sylvie; Blay, Jean-Yves.
Afiliação
  • Fayet Y; EMS Team-Human and Social Sciences Department, Centre Léon Bérard, 69008 Lyon, France.
  • Chevreau C; Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1, 69008 Lyon, France.
  • Decanter G; ICR IUCT-Oncopole, 31000 Toulouse, France.
  • Dalban C; Department of Surgical Oncology, Oscar Lambret Center, 59000 Lille, France.
  • Meeus P; Department of Clinical Research and Innovation, Centre Léon Bérard, 69008 Lyon, France.
  • Carrère S; Department of Surgery, Centre Léon Bérard, 69008 Lyon, France.
  • Haddag-Miliani L; Institut de Recherche en Cancérologie Montpellier, INSERM U1194, 34000 Montpellier, France.
  • Le Loarer F; Service D'imagerie Diagnostique, Institut Gustave Roussy, 94800 Villejuif, France.
  • Causeret S; Department of Pathology, Institut Bergonié, 33000 Bordeaux, France.
  • Orbach D; Centre Georges François Leclerc, 21000 Dijon, France.
  • Kind M; Centre Oncologie SIREDO (Soins, Innovation et Recherche en Oncologie de l'Enfant, de l'aDOlescents et de L'adulte Jeune), Institut Curie, Université de Recherche Paris Sciences et Lettres, 75005 Paris, France.
  • Le Nail LR; Radiologue, Département D'imagerie Médicale, Institut Bergonié, 33000 Bordeaux, France.
  • Ferron G; Department of Orthopaedic Surgery, CHU de Tours, Faculté de Médecine, Université de Tours, 37000 Tours, France.
  • Labrosse H; INSERM CRCT19 ONCO-SARC (Sarcoma Oncogenesis), Institut Claudius Regaud-Institut Universitaire du Cancer, 31000 Toulouse, France.
  • Chaigneau L; CRLCC Léon Berard, Oncology Regional Network ONCO-AURA, 69008 Lyon, France.
  • Bertucci F; Department of Medical Oncology, CHRU Jean Minjoz, 25000 Besançon, France.
  • Ruzic JC; Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
  • Le Brun Ly V; CHU Réunion, 97410 Saint-Pierre, France.
  • Farsi F; Service D'oncologie Médicale, CHU Dupuytren, 87000 Limoges, France.
  • Bompas E; CRLCC Léon Berard, Oncology Regional Network ONCO-AURA, 69008 Lyon, France.
  • Noal S; Medical Oncology Department, ICO, 44800 Saint Herblain, France.
  • Vozy A; UCP Sarcome, Centre François Baclesse, 14000 Caen, France.
  • Ducoulombier A; Department of Medical Oncology, Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), CLIP(2) Galilée, Sorbonne University, 75013 Paris, France.
  • Bonnet C; Centre Antoine-Lacassagne, 06000 Nice, France.
  • Chabaud S; Service d'Oncologie Médicale Hôpital Saint Louis, 75010 Paris, France.
  • Ducimetière F; Department of Clinical Research and Innovation, Centre Léon Bérard, 69008 Lyon, France.
  • Tlemsani C; Equipe EMS, Centre Léon Bérard, 69008 Lyon, France.
  • Ropars M; Service d'Oncologie Médicale, Hôpital Cochin, Institut du Cancer Paris CARPEM, Université de Paris, APHP Centre, 75014 Paris, France.
  • Collard O; INSERM U1016-CNRS UMR8104, Institut Cochin, Institut du Cancer Paris CARPEM, Université de Paris, APHP Centre, 75014 Paris, France.
  • Michelin P; Orthopaedic and Trauma Department, Pontchaillou University Hospital, University of Rennes 1, 35000 Rennes, France.
  • Gantzer J; Département d'Oncologie Médicale, Hôpital Privé de la Loire, 42100 Saint-Etienne, France.
  • Dubray-Longeras P; Service D'imagerie Médicale, CHU Hopitaux de Rouen-Hopital Charles Nicolle, 76000 Rouen, France.
  • Rios M; Department of Medical Oncology, Strasbourg-Europe Cancer Institute (ICANS), 67033 Strasbourg, France.
  • Soibinet P; Oncology Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
  • Le Cesne A; Department of Medical Oncology, Cancer Institute of Lorraine-Alexis Vautrin, 54500 Vandoeuvre Les Nancy, France.
  • Duffaud F; Department of Hepato-Gastroenterology and Digestive Oncology, Reims University Hospital, 51000 Reims, France.
  • Karanian M; Medical Oncology, Insitut Gustave Roussy, 94800 Villejuif, France.
  • Gouin F; Department of Medical Oncology, CHU La Timone and Aix-Marseille Université (AMU), 13005 Marseille, France.
  • Tétreau R; Department of Pathology, Lyon University Hospital, 69008 Lyon, France.
  • Honoré C; Department of Surgery, Centre Léon Bérard, 69008 Lyon, France.
  • Coindre JM; Medical Imaging Center, Institut du Cancer, 34000 Montpellier, France.
  • Ray-Coquard I; Department of Surgical Oncology, Gustave Roussy, Villejuif 94800, France.
  • Bonvalot S; Department of Pathology, Institut Bergonié, 33000 Bordeaux, France.
  • Blay JY; Department of Medical Oncology, Centre Leon Berard, 69008 Lyon, France.
Cancers (Basel) ; 14(11)2022 May 25.
Article em En | MEDLINE | ID: mdl-35681600
ABSTRACT
The national reference network NETSARC+ provides remote access to specialized diagnosis and the Multidisciplinary Tumour Board (MTB) to improve the management and survival of sarcoma patients in France. The IGéAS research program aims to assess the potential of this innovative organization to address geographical inequalities in cancer management. Using the IGéAS cohort built from the nationwide NETSARC+ database, the individual, clinical, and geographical determinants of the 3-year overall survival of sarcoma patients in France were analyzed. The survival analysis was focused on patients diagnosed in 2013 (n = 2281) to ensure sufficient hindsight to collect patient follow-up. Our study included patients with bone (16.8%), soft-tissue (69%), and visceral (14.2%) sarcomas, with a median age of 61.8 years. The overall survival was not associated with geographical variables after adjustment for individual and clinical factors. The lower survival in precarious population districts [HR 1.23, 95% CI 1.02 to 1.48] in comparison to wealthy metropolitan areas (HR = 1) found in univariable analysis was due to the worst clinical presentation at diagnosis of patients. The place of residence had no impact on sarcoma patients' survival, in the context of the national organization driven by the reference network. Following previous findings, this suggests the ability of this organization to go through geographical barriers usually impeding the optimal management of cancer patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article